15 documents found, page 1 of 2

BioMarrow

Preclinical models for multiple myeloma (MM) often fail to recapitulate the complexity of the bone marrow (BM) microenvironment, limiting their utility for drug testing and translational research. There is an urgent need for physiologically relevant, patient-adaptable platforms to support personalized therapeutic evaluation. We developed BioMarrow, a 3D ex vivo BM culture system using unmanipulated patient BM a...

Diagnosis and Laboratory Follow-Up of Patients with Multiple Myeloma: Guideline...

Multiple myeloma is a neoplasm of plasma cells that in most cases is associated with the secretion of monoclonal immunoglobulins and can involve multiple organs. Its timely diagnosis is essential to limit or avoid irreversible damage and dysfunction of target organs. Appropriate initial stratification of patients allows for optimization in the selection and sequence of therapy, as well as proper follow-up durin...

Diagnosis and laboratory follow-up of patients with multiple myeloma: guideline...

Multiple myeloma is a neoplasm of plasma cells that in most cases is associated with the secretion of monoclonal immunoglobulins and can involve multiple organs. Its timely diagnosis is essential to limit or avoid irreversible damage and dysfunction of target organs. Appropriate initial stratification of patients allows for optimization in the selection and sequence of therapy, as well as proper follow-up durin...

Portuguese real-world experience with ibrutinib for the treatment of relapsed/r...

Background: Mantle cell lymphoma is usually characterized by an aggressive and recurrent course. Clinical trials and real-world series have demonstrated clinical benefits with the use of ibrutinib as a second-line treatment, compared to later relapses. Objective: To evaluate the Portuguese experience with the use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma since its approval in the...

Multiple Myeloma Treatment Guidelines by the Portuguese Group of Multiple Myeloma

The treatment of multiple myeloma has profoundly changed with the introduction of several innovative therapies. The optimization of therapeutic sequencing through the combined use of the various drugs developed in recent years and the attention given to the characteristics of patients have allowed the reduction of toxicities and increased survival and quality of life of patients with multiple myeloma. These tre...

The immune microenvironment in multiple myeloma : friend or foe?

Multiple myeloma (MM) is one of the most prevalent hematological cancers worldwide, characterized by the clonal expansion of neoplastic plasma cells in the bone marrow (BM). A combination of factors is implicated in disease progression, including BM immune microenvironment changes. Increasing evidence suggests that the disruption of immunological processes responsible for myeloma control ultimately leads to the...

Statistical methods for the study of extracellular vesicles content and their p...

Definition of immunological nonresponse to antiretroviral therapy: a systematic...

Terms and criteria to classify people living with HIV on antiretroviral therapy who fail to achieve satisfactory CD4 T-cell counts are heterogeneous, and need revision and summarization. Background: Terms and criteria to classify people living with HIV on antiretroviral therapy who fail to achieve satisfactory CD4+ T-cell counts are heterogeneous, and need revision and summarization. Methods: We performed a sys...

Gamapatias Monoclonais de Significado Indeterminado: Critérios de Diagnóstico e...

O Grupo Português de Mieloma Múltiplo da Sociedade Portuguesa de Hematologia propôs-se criar um protocolo de avaliação e acompanhamento de doentes com gamapatias monoclonais. O protocolo aqui apresentado, meramente referencial, pretende racionalizar e uniformizar a forma como estes doentes são acompanhados pelos seus médicos assistentes e identifica critérios claros de risco de progressão que justificam a sua r...

Gamapatias Monoclonais de Significado Indeterminado: Critérios de Diagnóstico e...

O Grupo Português de Mieloma Múltiplo da Sociedade Portuguesa de Hematologia propôs-se criar um protocolo de avaliação e acompanhamento de doentes com gamapatias monoclonais. O protocolo aqui apresentado, meramente referencial, pretende racionalizar e uniformizar a forma como estes doentes são acompanhados pelos seus médicos assistentes e identifica critérios claros de risco de progressão que justificam a sua r...